CN1304575C - 预防黄病毒感染的核酸疫苗 - Google Patents

预防黄病毒感染的核酸疫苗 Download PDF

Info

Publication number
CN1304575C
CN1304575C CNB02807758XA CN02807758A CN1304575C CN 1304575 C CN1304575 C CN 1304575C CN B02807758X A CNB02807758X A CN B02807758XA CN 02807758 A CN02807758 A CN 02807758A CN 1304575 C CN1304575 C CN 1304575C
Authority
CN
China
Prior art keywords
virus
nucleic acid
flavivirus
antigen
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB02807758XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1500152A (zh
Inventor
张光正
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centers of Disease Control and Prevention CDC
Original Assignee
Centers of Disease Control and Prevention CDC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centers of Disease Control and Prevention CDC filed Critical Centers of Disease Control and Prevention CDC
Publication of CN1500152A publication Critical patent/CN1500152A/zh
Application granted granted Critical
Publication of CN1304575C publication Critical patent/CN1304575C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
CNB02807758XA 2001-04-04 2002-04-04 预防黄病毒感染的核酸疫苗 Expired - Lifetime CN1304575C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/826,115 US7227011B2 (en) 1998-06-04 2001-04-04 Nucleic acid vaccines for prevention of flavivirus infection
US09/826,115 2001-04-04

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA2007100020999A Division CN101002936A (zh) 2001-04-04 2002-04-04 预防黄病毒感染的核酸疫苗

Publications (2)

Publication Number Publication Date
CN1500152A CN1500152A (zh) 2004-05-26
CN1304575C true CN1304575C (zh) 2007-03-14

Family

ID=25245753

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB02807758XA Expired - Lifetime CN1304575C (zh) 2001-04-04 2002-04-04 预防黄病毒感染的核酸疫苗
CNA2007100020999A Pending CN101002936A (zh) 2001-04-04 2002-04-04 预防黄病毒感染的核酸疫苗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA2007100020999A Pending CN101002936A (zh) 2001-04-04 2002-04-04 预防黄病毒感染的核酸疫苗

Country Status (11)

Country Link
US (6) US7227011B2 (enExample)
EP (3) EP2332572B1 (enExample)
JP (2) JP4448281B2 (enExample)
KR (1) KR100913984B1 (enExample)
CN (2) CN1304575C (enExample)
BR (1) BRPI0208301B8 (enExample)
CA (1) CA2443323C (enExample)
MX (1) MXPA03008838A (enExample)
NZ (1) NZ529106A (enExample)
WO (1) WO2002081754A1 (enExample)
ZA (1) ZA200307580B (enExample)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7227011B2 (en) * 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
AU2001227889A1 (en) 2000-01-14 2001-07-24 The United States of America, represented by The Secretary, Department of Health & Human Services Oligodeoxynucleotide and its use to induce an immune response
US20040037848A1 (en) * 2001-04-06 2004-02-26 Audonnet Jean-Christophe Francis Recombinant vaccine against West Nile Virus
US7740863B2 (en) * 2001-04-06 2010-06-22 Merial Recombinant vaccine against West Nile Virus
US20050031641A1 (en) * 2001-04-06 2005-02-10 Loosmore Sheena May Recombinant vaccine against West Nile Virus
FR2823222B1 (fr) * 2001-04-06 2004-02-06 Merial Sas Vaccin contre le virus de la fievre du nil
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
PL212212B1 (pl) * 2001-07-27 2012-08-31 Wyeth Corp Kompozycja szczepionki przeciwko zakażeniu wirusem Zachodniego Nilu, kompozycja końskiej szczepionki, szczepionka wirusa Zachodniego Nilu oraz zastosowania
US7354909B2 (en) * 2001-08-14 2008-04-08 The United States Of America As Represented By Secretary Of The Department Of Health And Human Services Method for rapid generation of mature dendritic cells
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
AU2002366710A1 (en) * 2001-12-20 2003-07-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
AU2003263853A1 (en) * 2002-08-16 2004-03-03 Board Of Regents The University Of Texas System Compositions and methods related to flavivirus envelope protein domain iii antigens
US8263091B2 (en) * 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
AU2003296921A1 (en) * 2002-10-31 2004-05-25 Health Research, Inc. Diagnostic test for west nile virus
ES2390874T3 (es) * 2002-11-08 2012-11-19 The Administrators Of The Tulane Educational Fund Inhibidores de fusión de flavivirus
CA2432738A1 (en) * 2003-02-26 2004-08-26 Philippe Despres New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications
EP1626708B1 (en) 2003-05-23 2017-11-29 Novartis Vaccines and Diagnostics, Inc. Immunogenic reagents from west nile virus
US7060280B2 (en) * 2003-06-11 2006-06-13 Academia Sinica Immunization against flavivirus
WO2005024427A2 (en) * 2003-09-09 2005-03-17 Idexx Laboratories, Inc. Detection of west nile virus infection and vaccination
US7074555B2 (en) 2004-04-28 2006-07-11 Idexx Laboratories, Inc. Detection of West Nile Virus
EP1742963A2 (en) * 2004-05-04 2007-01-17 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Synthesis and purification of west nile virus virus-like particles
CN103088038B (zh) * 2004-07-12 2015-06-24 美国天甲生物医药有限公司 黄病毒疫苗
CA2576798C (en) 2004-07-27 2014-09-09 Gwong-Jen J. Chang Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes and methods for their use
WO2006029300A2 (en) * 2004-09-09 2006-03-16 Research Development Foundation Flavivirus variants having phenotypic variation and immunogenic compositions thereof
NZ584079A (en) * 2004-10-20 2011-10-28 Acambis Inc Vaccines against japanese encephalitis virus and west nile virus
AU2006232865A1 (en) * 2005-04-01 2006-10-12 Wyeth Use of WNV DNA vaccine in combination with a conventional vaccine to overcome immunogen interference
CN104815327A (zh) 2005-04-08 2015-08-05 惠氏有限责任公司 多价肺炎球菌多糖-蛋白质缀合物组合物
US8048429B2 (en) * 2005-06-24 2011-11-01 Intervet International B.V. Inactivated chimeric flavivirus
US7455842B2 (en) * 2005-12-05 2008-11-25 University Of Kansas Chimeric West Nile viruses and uses thereof
US20070190617A1 (en) * 2006-02-13 2007-08-16 Chang-Jer Wu DNA vaccine for Japanese encephalitis virus
US20080044808A1 (en) * 2006-08-15 2008-02-21 Qian-Li Song West nile virus antigen and assay
EP2462930B1 (en) * 2006-11-09 2017-05-31 The United States Of America As Represented By The Secretary Of The Navy Induction of an immune response against dengue virus using prime-boost approach
DK2308514T3 (da) 2007-03-23 2013-09-02 To Bbb Holding B V Konjugater til målrettet lægemiddeltransport gennem blod-hjerne barrieren
JP2008263964A (ja) * 2007-03-29 2008-11-06 Yamaguchi Univ コウモリ由来細胞株
EP2003144A1 (en) * 2007-06-15 2008-12-17 Institut Pasteur Method for the diagnosis or the screening of an arbovirus infection, reagents useful in said method and their applications
WO2009024534A2 (en) * 2007-08-17 2009-02-26 Intercell Ag Japanese encephalitis virus (jev) and tick-borne encephalitis virus (tbev) peptides stimulating human t cell responses
US8138318B2 (en) * 2007-09-13 2012-03-20 Abbott Laboratories Hepatitis B pre-S2 nucleic acid
WO2009099716A1 (en) * 2008-01-11 2009-08-13 Vgx Pharmaceuticals, Inc. Novel vaccines against multiple subtypes of dengue virus
US8715999B2 (en) * 2008-02-08 2014-05-06 Valneva Austria Gmbh Flaviviridae mutants comprising a deletion in the capsid protein for use as vaccines
CA2721657A1 (en) * 2008-04-22 2009-10-29 Cytos Biotechnology Ag Vaccine compositions for the treatment of dengue fever and uses thereof
CN101333246B (zh) * 2008-07-30 2011-04-13 中国农业科学院哈尔滨兽医研究所 乙型脑炎病毒e蛋白中和性b细胞抗原表位多肽及其应用
BRPI0918897B1 (pt) 2008-08-29 2021-06-15 Boehringer Ingelheim Animal Health USA Inc. Composição imunogênica e seus usos
CN101607983B (zh) * 2009-07-29 2012-06-13 中国农业科学院哈尔滨兽医研究所 乙型脑炎病毒PrM/M蛋白B细胞抗原表位多肽及应用
DK2459709T3 (en) 2009-07-31 2014-12-01 Ge Healthcare Bio Sciences HIGH-REPLACED YELLOW FEBER VIRUS TREASURY WITH INCREASED CELL STORAGE
US20110182976A1 (en) * 2010-01-28 2011-07-28 National Taiwan Ocean University Lipoplex-patch based dna vaccine
MX2012012681A (es) 2010-05-21 2012-12-17 Univ Pittsburgh Secuencias del virus de dengue universales y metodos de uso.
AR079970A1 (es) * 2010-07-23 2012-02-29 Xcellerex Inc Cepas de alto rendimiento del virus de la fiebre amarilla con una propagacion incrementada en las celulas
US20120294889A1 (en) * 2010-11-12 2012-11-22 Paxvax, Inc. Chimeric Flavivirus Vaccines
MX350718B (es) 2011-03-14 2017-09-14 Boehringer Ingelheim Vetmedica Inc Vacuna de rinitis equina.
US20140286983A1 (en) 2011-10-20 2014-09-25 The Government of the USA as represented by the Secretaryof the Dept. of Health and Human Services Dengue virus e-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes
US8920804B2 (en) 2011-12-22 2014-12-30 Inbios International, Inc. Methods and materials for the detection of dengue virus infection
WO2014016362A1 (en) * 2012-07-24 2014-01-30 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
TWI852899B (zh) 2014-09-02 2024-08-21 法商賽諾菲巴斯德公司 疫苗組合物
EP3031923A1 (en) 2014-12-11 2016-06-15 Institut Pasteur Lentiviral vector-based japanese encephalitis immunogenic composition
CN104630160B (zh) * 2015-01-23 2018-04-27 中国农业科学院哈尔滨兽医研究所 表达西尼罗热病毒PrM/E蛋白的重组新城疫LaSota疫苗株
EP3316905A1 (en) 2015-07-03 2018-05-09 Sanofi Pasteur Concomitant dengue and yellow fever vaccination
EP4218805A1 (en) * 2015-07-21 2023-08-02 ModernaTX, Inc. Infectious disease vaccines
WO2017218339A1 (en) * 2016-06-13 2017-12-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nucleic acids encoding zika virus-like particles and their use in zika virus vaccines and diagnostic assays
US20180028643A1 (en) * 2016-06-21 2018-02-01 Brock Adam Kingstad-Bakke Zika virus vaccines using virus-like particles
US10898566B2 (en) 2016-09-19 2021-01-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Zika virus vaccines
US11780885B2 (en) * 2016-11-17 2023-10-10 Glaxosmithkline Biologicals Sa Zika viral antigen constructs
WO2018152526A1 (en) 2017-02-20 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Zika virus vaccines
JP7313345B2 (ja) 2017-10-05 2023-07-24 サノフィ・パスツール デング熱に対するブースターワクチン接種のための組成物
EP3755709A1 (en) * 2018-02-22 2020-12-30 Euroimmun Medizinische Labordiagnostika AG Assay for the diagnosis of viral infections
EP3530668A1 (en) * 2018-02-22 2019-08-28 Euroimmun Medizinische Labordiagnostika AG A novel assay for the diagnosis of viral infections
CN113372441B (zh) * 2018-04-04 2023-03-10 中国科学院微生物研究所 一种高灵敏度的黄热病毒人源单克隆抗体及其应用
CN108904793B (zh) * 2018-07-29 2021-03-30 首都医科大学附属北京友谊医院 预防流行性乙型脑炎的dna疫苗及其构建方法
US20220054620A1 (en) * 2018-12-20 2022-02-24 The Wistar Institute Of Anatomy And Biology Vaccines against powassan virus, and methods of using same
CA3162377A1 (en) * 2019-12-18 2021-06-24 Joel MASLOW Powassan viral antigens and related compositions, and uses thereof to vaccinate and treat patients
KR102216078B1 (ko) * 2020-04-22 2021-02-16 국방과학연구소 유전자 백신으로 사용하기 위한 항원 유전자 전달용 발현 벡터 및 이를 포함하는 유전자 백신
US20230272405A1 (en) * 2020-06-22 2023-08-31 University Of Connecticut Flavivirus signal peptides, vaccine constructs, and methods therefor
EP4612495A1 (en) * 2022-11-02 2025-09-10 Takeda Vaccines, Inc. A method for determining the infectivity of a virus

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5494671A (en) * 1990-08-27 1996-02-27 The United States Of America As Represented By The Department Of Health And Human Services C-terminally truncated dengue and Japanese encephalitis virus envelope proteins
CN1253506A (zh) * 1997-02-28 2000-05-17 奥拉瓦克斯公司 嵌合黄病毒疫苗
US6165477A (en) * 1995-05-24 2000-12-26 Hawaii Biotechnology Group, Inc. Subunit immonogenic composition against dengue infection

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1601438A (enExample) 1968-10-17 1970-08-24
JPS53133627A (en) 1977-04-25 1978-11-21 Nippon Seibutsu Kagaku Kenkiyu High purity deactivated vaccine for japanese encephalitis
JPH0768267B2 (ja) * 1986-06-05 1995-07-26 財団法人阪大微生物病研究会 フラビウイルス抗原
JPS634895A (ja) 1986-06-24 1988-01-09 Mitsubishi Electric Corp オゾン精製水供給装置
JPS63105682A (ja) 1986-10-23 1988-05-10 Mitsubishi Kasei Corp デングウイルス３型由来のｃＤＮＡ
FR2614219B1 (fr) 1987-04-23 1993-07-09 Materiels Annexes Dialyse Procede de fabrication de granules destines a la preparation de solutions de dialyse et installation pour sa mise en oeuvre.
JPH084508B2 (ja) * 1987-09-16 1996-01-24 国立予防衛生研究所長 組み換えワクチニアウイルス
US4783502A (en) 1987-12-03 1988-11-08 Ppg Industries, Inc. Stable nonaqueous polyurethane microparticle dispersion
JP2511494B2 (ja) * 1988-05-12 1996-06-26 善治 松浦 日本脳炎ウイルス表面抗原蛋白質の製造法
IL91304A0 (en) 1988-08-20 1990-03-19 Us Health Recombinant vaccinia virus for prevention of disease caused by flavivirus
JPH0425408A (ja) 1990-05-21 1992-01-29 Hitachi Ltd ペレタイジングシステムの自動連続運転制御方法
FR2665710A1 (fr) 1990-08-10 1992-02-14 Pasteur Institut Baculovirus recombinant exprimant les proteines e et ns1 de virus appartenant aux flaviviridae ou de virus apparentes aux flaviviridae, applications diagnostiques et therapeutiques.
US5514375A (en) * 1990-08-15 1996-05-07 Virogenetics Corporation Flavivirus recombinant poxvirus vaccine
MY109299A (en) 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE310824T1 (de) 1991-09-19 2005-12-15 Chimäre und/oder wachstumsgehemmte flaviviren
JPH05276941A (ja) 1992-02-28 1993-10-26 Nippon Zeon Co Ltd フラビウイルス科に属するウイルスの表面抗原タンパク質を含む非感染性の構造物粒子の製造方法
JPH07265093A (ja) 1994-03-30 1995-10-17 Chemo Sero Therapeut Res Inst 哺乳動物細胞を用いる日本脳炎ウイルス表面抗原蛋白質の製法
US6136561A (en) * 1995-05-24 2000-10-24 Hawaii Biotechnology Group, Inc. Methods of preparing carboxy-terminally truncated recombinant flavivirus envelope glycoproteins employing drosophila melanogaster expression systems
US6074865A (en) * 1995-07-20 2000-06-13 The United States Of America As Represented By The Secretary Of The Army Recombinant dengue virus DNA fragment
US6455509B1 (en) * 1996-06-04 2002-09-24 The United States Of America As Represented By The Secretary Of The Navy Dengue nucleic acid vaccines that induce neutralizing antibodies
US6962708B1 (en) * 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
KR20010022452A (ko) 1997-07-31 2001-03-15 추후제출 플라비바이러스 감염에 대한 재조합 다이머형 엔벨롭 백신
US6258788B1 (en) 1997-11-20 2001-07-10 The United States Of America As Represented By The Secretary Of The Army DNA vaccines against tick-borne flaviviruses
US7227011B2 (en) * 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
AU778988B2 (en) 1998-06-04 2004-12-23 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Nucleic acid vaccines for prevention of flavivirus infection
AU2002305028A1 (en) 2001-02-28 2002-10-28 Brown University Research Foundation West nile virus epitopes and uses thereof
AU2002309508A1 (en) 2001-03-12 2002-09-24 L2 Diagnostics, Llc Compositions and methods comprising west nile virus polypeptides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5494671A (en) * 1990-08-27 1996-02-27 The United States Of America As Represented By The Department Of Health And Human Services C-terminally truncated dengue and Japanese encephalitis virus envelope proteins
US6165477A (en) * 1995-05-24 2000-12-26 Hawaii Biotechnology Group, Inc. Subunit immonogenic composition against dengue infection
CN1253506A (zh) * 1997-02-28 2000-05-17 奥拉瓦克斯公司 嵌合黄病毒疫苗

Also Published As

Publication number Publication date
US20100040643A1 (en) 2010-02-18
CN101002936A (zh) 2007-07-25
EP2332572B1 (en) 2014-01-08
BRPI0208301A8 (pt) 2018-11-27
EP1935991A2 (en) 2008-06-25
MXPA03008838A (es) 2004-10-15
CN1500152A (zh) 2004-05-26
US7632510B2 (en) 2009-12-15
HK1062836A1 (en) 2004-11-26
US20070166701A1 (en) 2007-07-19
US20030022849A1 (en) 2003-01-30
US7662394B2 (en) 2010-02-16
JP5236597B2 (ja) 2013-07-17
CA2443323C (en) 2013-01-15
NZ529106A (en) 2005-03-24
EP1383931A4 (en) 2004-12-22
ZA200307580B (en) 2005-03-30
US8232379B2 (en) 2012-07-31
EP2332572A1 (en) 2011-06-15
US7227011B2 (en) 2007-06-05
BRPI0208301B8 (pt) 2021-05-25
JP2004532023A (ja) 2004-10-21
US20070166329A1 (en) 2007-07-19
WO2002081754A1 (en) 2002-10-17
JP2010017185A (ja) 2010-01-28
EP1935991B1 (en) 2012-11-07
JP4448281B2 (ja) 2010-04-07
US20100003273A1 (en) 2010-01-07
US7521177B2 (en) 2009-04-21
EP1383931A1 (en) 2004-01-28
BR0208301A (pt) 2004-03-09
CA2443323A1 (en) 2002-10-17
US20050163804A1 (en) 2005-07-28
KR100913984B1 (ko) 2009-08-25
EP1935991A3 (en) 2008-09-10
US8221768B2 (en) 2012-07-17
BRPI0208301B1 (pt) 2019-12-24
KR20030092051A (ko) 2003-12-03

Similar Documents

Publication Publication Date Title
CN1304575C (zh) 预防黄病毒感染的核酸疫苗
US8105609B2 (en) Flavivirus immunogens comprising extracellular viral particles composed of the premembrane (prM) and envelope (E) antigens
AU2016363696B2 (en) Single variable domain T-cell receptors
CN113631033B (zh) 与enpp1或enpp3缺乏有关的疾病的治疗
CN1636050A (zh) 核心糖基化hcv包膜蛋白
KR20170004967A (ko) 비-펩티드 결합을 함유하는 하이브리드 면역글로불린
KR101201020B1 (ko) 감마-카르복실화된 단백질의 제조 방법
CN1717417A (zh) 用于治疗和预防毒性及病原体介导的疾病的新的免疫粘附素
CN114616000A (zh) 载体组合物及其用于治疗溶酶体贮积症的方法
US20240148907A1 (en) Liver specific production of enpp1 or enpp3
CN115707776B (zh) 重组柯萨奇病毒a6病毒样颗粒及其用途
CN103773803A (zh) 表达猪o型口蹄疫病毒vp1蛋白的重组牛副流感病毒载体
TW202228728A (zh) 用於同時調節基因表現之組合物及方法
CN111886342A (zh) 拉沙疫苗
CN110423736B (zh) 碱基编辑工具及其应用以及在真核细胞内进行宽窗口和无序列偏好性碱基编辑的方法
HK1062836B (en) Nucleic acid vaccines for prevention of flavivirus infection
KR20070114761A (ko) Ｓｉｖ­ｐｅｄｆ 벡터를 사용한 안조직 세포에 있어서의아포토시스 변성을 동반하는 질환의 치료제
CN113652412A (zh) 一种制备限制性内切酶类产品的方法
CN101160139A (zh) 含有pedf以及fgf2的伴随眼组织细胞凋亡变性的疾患的治疗药物
US20050003344A1 (en) AAV2 Rep protein fusions
CN114231568B (zh) 一种提高dna修复效率的辅助蛋白及其基因编辑载体和应用
HK40063782A (en) Treatment of diseases involving deficiency of enpp1 or enpp3
CN116710108A (zh) 用于同时调节诸基因表达的组合物和方法
CN1772304A (zh) 柯萨奇病毒b组2型基因疫苗
HK40063782B (zh) 与enpp1或enpp3缺乏有关的疾病的治疗

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1062836

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1062836

Country of ref document: HK

CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20070314